Currently, there are five FDA-approved HDAC inhibitors (HDAC-i) available for cancer treatment: Vorinostat (SAHA), Belinostat (PXD-101), Romidepsin (FK-228), Epidaza (HBI-8000), and Panobinostat (LBH589) [37]. Here, HDAC9 is linked to cancer.